Macrocyclic LRRK2 Kinase Inhibitors With Dual-Site Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurological disorders such as Parkinson's disease, Alzheimer's disease, cardiac diseases, and inflammatory disorders like Crohn's disease lack effective treatments to prevent or slow progression, and existing LRRK2 inhibitors have limitations in potency and selectivity.
Innovation Solution
Development of novel macrocyclic compounds that act as selective LRRK2 kinase inhibitors, targeting specific domains to modulate kinase activity and address underlying disease mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing LRRK2 inhibitors are used, then kinase activity is inhibited, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies local quality by designing the macrocyclic compound with distinct functional regions: a kinase domain-binding portion that specifically targets the ATP-binding site of LRRK2, and a separate portion that extends into the allosteric site. This spatial differentiation of binding functions enhances both potency (through strong ATP-site anchoring) and selectivity (through unique allosteric interactions not present in other kinases)
Solution Approach 2:
The invention employs composite material principles by creating a hybrid macrocyclic structure that combines rigid cyclic components with flexible linker regions. The macrocycle incorporates diverse functional groups (amide, carbamate, heterocyclic rings) within a single molecular framework, enabling multi-point binding to LRRK2 with high affinity and selectivity that simpler inhibitor structures cannot achieve
2Ease of operation
If standard dopamine replacement therapy is used, then motor complications are relieved symptomatically, but disease progression cannot be prevented
Solution Approach 1:
The patent extracts the underlying pathological mechanism (LRRK2 kinase activity) from the symptomatic manifestations of Parkinson's disease. By specifically inhibiting LRRK2, the compound addresses the root cause of dopaminergic neuron degeneration rather than merely replacing dopamine, thereby potentially preventing disease progression while maintaining motor function
3Ease of operation
If current Parkinson's disease therapies are used, then motor symptoms are managed, but no approved therapy exists to prevent or delay progression
Solution Approach 1:
The patent implements preliminary action by using LRRK2 inhibition to prevent the downstream pathological events that lead to dopaminergic neuron loss and disease progression. By blocking the kinase activity early in the pathological cascade, the compound aims to prevent neuronal degeneration before it occurs, thereby extending the duration of disease-free state beyond what symptomatic therapies can achieve
Data Source
AI summary
Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.